FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.

Bristol Myers Squibb - Recent News & Activity

Bristol Myers Squibb - Recent News & Activity

US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

FDA accepts Bristol Myers application for Breyanzi for CLL, SLL (BMY)

Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

BMS' CAR-T pressures Gilead in 2L lymphoma with broader nod

Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

CBRE completes $146M-sale of 1,035-apartment housing portfolio - NJBIZ

Reblozyl® (luspatercept-aamt) Access and Financial Resources